Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation

From clinical trials to public allocation - a Johns Hopkins University and University of Washington Symposium

There are now more than 33 million confirmed COVID-19 cases worldwide and the death toll of the global pandemic is nearing 1 million. The United States remains the most affected country, with more than 7 million diagnosed COVID-19 infections and upwards of 200,000 deaths to date. The pandemic has also had enormous social and economic impacts globally, and continues to challenge families, communities, health systems, and virtually every aspect of society.

Efforts to develop COVID-19 vaccines are well underway, and protecting the scientific integrity of the process is paramount. The trials must be—and must be seen to be—free of political interference, carried out with the highest scientific and ethical rigor, and allowed to proceed until the safety and efficacy of each candidate vaccine has been thoroughly assessed. The ultimate goal is global distribution of and equitable access to effective vaccines that can help slow, and eventually end, the pandemic.

With this backdrop, Johns Hopkins University and the University of Washington are bringing together leading experts to explore these issues and put forward a concise plan for protecting the scientific integrity of these lifesaving efforts. “Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation” will feature insights from global leaders in vaccine science, health metrics, policy, regulation, and communications.

This virtual symposium will focus on several key areas:

  • The science behind COVID-19 vaccine-efficacy trials
  • Essential elements of protecting scientific integrity
  • Frameworks for assessing vaccine safety and efficacy, including emergency use authorizations (EUAs)
  • Ethical aspects of COVID-19 trials
  • Ensuring trials are inclusive, diverse, and allow for assessment of highly affected communities
  • Vaccine access and allocation in the U.S. and globally
Date
- Add to Calendar 2020-10-06 13:30:00 2020-10-06 16:45:00 Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation https://www.washington.edu/populationhealth/vaccinesymposium/?utm_source=uwhp&utm_medium=tiles&utm_campaign=covid-19-symposium

There are now more than 33 million confirmed COVID-19 cases worldwide and the death toll of the global pandemic is nearing 1 million. The United States remains the most affected country, with more than 7 million diagnosed COVID-19 infections and upwards of 200,000 deaths to date. The pandemic has also had enormous social and economic impacts globally, and continues to challenge families, communities, health systems, and virtually every aspect of society.

Efforts to develop COVID-19 vaccines are well underway, and protecting the scientific integrity of the process is paramount. The trials must be—and must be seen to be—free of political interference, carried out with the highest scientific and ethical rigor, and allowed to proceed until the safety and efficacy of each candidate vaccine has been thoroughly assessed. The ultimate goal is global distribution of and equitable access to effective vaccines that can help slow, and eventually end, the pandemic.

With this backdrop, Johns Hopkins University and the University of Washington are bringing together leading experts to explore these issues and put forward a concise plan for protecting the scientific integrity of these lifesaving efforts. “Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation” will feature insights from global leaders in vaccine science, health metrics, policy, regulation, and communications.

This virtual symposium will focus on several key areas:

  • The science behind COVID-19 vaccine-efficacy trials
  • Essential elements of protecting scientific integrity
  • Frameworks for assessing vaccine safety and efficacy, including emergency use authorizations (EUAs)
  • Ethical aspects of COVID-19 trials
  • Ensuring trials are inclusive, diverse, and allow for assessment of highly affected communities
  • Vaccine access and allocation in the U.S. and globally
https://clic-ctsa.org/events/preserving-scientific-integrity-getting-covid-19-vaccines-clinical-trials-public-allocation Johns Hopkins University University Of Washington admin@clic-ctsa.org America/New_York public
Activity Type
Symposium
Location Type
Online
https://www.washington.edu/populationhealth/vaccinesymposium/?utm_source=uwhp&u…